Accelerated Approval Submission On The HORIZON For Oncopeptides’ Melflufen

 
• By Bridget Silverman

US FDA says Phase II HORIZON data in relapsed triple-class refractory multiple myeloma can support NDA; Oncopeptides aims for submission Q1 2020.

Multiple myeloma (showing flame-shaped plasma cell) - Image
Recent regulatory discussions on Oncopeptides multiple myeloma candidate were “even better than we anticipated.” • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards